(Q44382485)

2 December 2017

title

The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation (English)

1 reference

2 December 2017

0 references

ankylosing spondylitis

1 reference

Mehmet Soy

5

0 references

author name string

Ozden Arısoy

1

1 reference

2 December 2017

Cemal Bes

2

1 reference

2 December 2017

Cigdem Cifci

3

1 reference

2 December 2017

Mustafa Sercan

4

1 reference

2 December 2017

language of work or name

1 reference

20 January 2013

1 reference

Rheumatology International

2 December 2017

published in

1 reference

2 December 2017

volume

33

1 reference

2 December 2017

issue

7

1 reference

2 December 2017

page(s)

1855-1864

1 reference

https://scigraph.springernature.com/pub.10.1007/s00296-013-2671-x

2 December 2017

exact match

0 references

cites work

Ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Psychological status and patient-assessed health instruments in ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Disease and psychological status in ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Mood disorders in the medically ill: scientific review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Cytokines sing the blues: inflammation and the pathogenesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

The concept of depression as a dysfunction of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Cytokines and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Psychiatric side effects of interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Identification and treatment of symptoms associated with inflammation in medically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

A meta-analysis of cytokines in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

TNF-mediated inflammatory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

TNFalpha blockade in human diseases: an overview of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Infliximab improves quality of life in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Anti-inflammatory drugs in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Cytokine–serotonin interaction through IDO: a neurodegeneration hypothesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-013-2671-X

Serum levels of IL-1 beta, TNF-alpha, IL-8, and acute phase proteins in seronegative spondyloarthropathies

21 January 2018

1 reference

12 December 2020

Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis

1 reference

12 December 2020

Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

1 reference

12 December 2020

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

1 reference

12 December 2020

Treatment of ankylosing spondylitis: focus on etanercept.

1 reference

12 December 2020

Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level

1 reference

12 December 2020

The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters

1 reference

12 December 2020

[Quality of life of patients with rheumatoid arthritis undergoing out-patient treatment with TNF inhibitors]

1 reference

12 December 2020

Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor.

1 reference

12 December 2020

Gender, depression, and ankylosing spondylitis

1 reference

12 December 2020

1 reference

12 December 2020

Cytokine-induced sickness behavior: mechanisms and implications

1 reference

12 December 2020

10.1007/S00296-013-2671-X

Identifiers

DOI

1 reference

2 December 2017

1 reference